Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Haematology & Bone Marrow Transplant
Allogeneic bone marrow transplant (unrelated donor)
What an allogeneic bone marrow transplant (unrelated donor) involves, how matched unrelated donors (MUD) are identified, the conditioning and engraftment timeline, approximate costs in Turkey compared with the UK, US, and Germany, managing graft-versus-host disease (GvHD) and infection risks, hospital isolation protocols, long-term immune recovery, and how to evaluate accredited international transplant centres.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Haematology & Bone Marrow Transplant
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Allogeneic Bone Marrow Transplant (Unrelated Donor)
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
Does an allogeneic bone marrow transplant actually work?
Decades of clinical registry data from the EBMT and CIBMTR confirm that allogeneic transplantation is an established, curative treatment for acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), myelodysplastic syndromes (MDS), and severe aplastic anaemia. Long-term disease-free survival depends primarily on disease stage at transplant, donor HLA compatibility, and patient physical fitness.
Transplantation performed during complete haematological remission produces significantly higher cure rates than procedures during active relapse. However, the graft-versus-leukaemia benefit must be weighed against treatment-related mortality from infection, organ toxicity, and GvHD. Reputable haematologists evaluate risk scores such as the EBMT score or HCT-CI to provide honest expectations rather than speculative promises.
MUD transplant, sibling donor or haploidentical: how do donor types compare?
Selecting a donor source depends on HLA compatibility, sibling availability, patient fitness, and disease urgency. Clinical teams assess several cellular therapy strategies.
| Transplant type | Best suited to | Typical limits |
|---|---|---|
| Matched unrelated donor (MUD) | Patients without a compatible sibling who have an 8/8 or 10/10 registry match | Donor search takes 4–12 weeks; higher risk of GvHD than a matched sibling |
| Matched related donor (MSD) | Patients with a fully HLA-identical biological brother or sister | Only about 25–30% of patients have an identical sibling match available |
| Haploidentical (half-match) | Urgent cases needing immediate transplantation with a half-matched family donor | Requires intensive post-transplant cyclophosphamide to control GvHD |
| Autologous transplant | Lymphoma or multiple myeloma using the patient's own harvested stem cells | Not suitable for leukaemia or marrow failure as diseased cells can re-enter |
A matched sibling remains the first choice for lower GvHD rates, but matched unrelated donors achieve comparable long-term disease control when 10/10 matching is achieved. Review how it works to see how donor compatibility reports are evaluated.
The transplant process: conditioning, infusion and engraftment step by step
The clinical procedure follows three distinct stages in an accredited hospital:
Conditioning (Days -7 to -1): Patients are admitted to private HEPA-filtered positive-pressure isolation rooms. High-dose chemotherapy (such as busulfan, fludarabine, or cyclophosphamide), occasionally with total body irradiation, eliminates residual cancer cells, empties marrow space, and suppresses host immunity.
Stem cell infusion (Day 0): Processed stem cells from the unrelated donor are infused through a central venous catheter over one to four hours, with continuous monitoring of vital signs.
Aplastic phase and engraftment (Days +1 to +28): Blood counts drop sharply. The patient receives prophylactic antimicrobials, immunosuppressants (cyclosporine or tacrolimus with methotrexate), and blood transfusions. Engraftment occurs when absolute neutrophil counts exceed 500 cells per microlitre for three consecutive days, typically between Day +14 and Day +24.
Results and remission: what does success look like after transplantation?
Results in allogeneic transplantation are defined by haematological remission and chimerism rather than cosmetic appearances. Before-and-after recovery cannot be judged from photographs: while hair regrows and physical stamina returns over months, true success means no detectable malignant cells and durable marrow function.
Chimerism analysis at Day +30, +60, and +100 measures the proportion of donor cells in the patient's blood and marrow. Full donor chimerism (100% donor haematopoiesis) confirms successful replacement. Our team collaborates with specialist units across our network of oncology treatments in Turkey to verify cellular therapy protocols and post-transplant standards.
Risks and complications: GvHD, infection and graft rejection
Allogeneic transplantation involves major medical risks. Key complications recognised by the EBMT and NHS include:
- Graft-versus-host disease (GvHD): Acute GvHD occurs when donor T-cells attack host skin, liver, or gut within 100 days. Chronic GvHD develops later, affecting skin, joints, eyes, and mouth. Treatment involves corticosteroids and targeted immunosuppressants.
- Infections: Profound immune suppression creates vulnerability to bacterial, viral (CMV reactivation), and fungal infections (Aspergillus). Prophylactic medication and regular PCR monitoring are mandatory.
- Graft rejection: Host lymphocytes rarely reject donor cells, requiring emergency haematological intervention.
- Organ toxicity: Conditioning drugs can cause hepatic sinusoidal obstruction syndrome (SOS/VOD) or pulmonary complications.
- Late effects: Endocrine dysfunction, infertility, cataracts, and secondary malignancies necessitate lifelong surveillance.
How to choose an accredited transplant centre and red flags
Selecting an allogeneic bone marrow transplant (unrelated donor) Turkey centre demands verifying international quality standards. The internationally recognised cellular therapy credential is JACIE (Joint Accreditation Committee ISCT-Europe & EBMT) or FACT accreditation.
Key requirements to check:
- Current JACIE or FACT accreditation for allogeneic cellular therapy.
- HEPA-filtered positive-pressure private isolation rooms.
- On-site stem cell processing laboratory and 24/7 ICU support.
- Integration with international donor registries (WMDA/BMDW).
- Dedicated clinical haematologists and round-the-clock nursing.
Questions to ask the clinic:
- Is your transplant unit currently JACIE-accredited for allogeneic unrelated transplants?
- How many matched unrelated donor transplants does your haematology team perform annually?
- What are your documented rates of engraftment, acute GvHD, and transplant-related mortality?
- How are post-discharge emergencies and day-hospital visits managed after hospital discharge?
- What telemedicine and coordination protocol exists with my home haematologist?
Red flags include clinics offering cellular therapies without JACIE accreditation, teams quoting prices without reviewing bone marrow biopsy reports, lack of HEPA-filtered isolation rooms, and guarantees of cure. Consult how it works to understand registry coordination, or request a free quote to receive a verified hospital plan.
Hospitals with Oncology in Turkey
Frequently asked questions
An allogeneic bone marrow transplant (unrelated donor) replaces damaged or cancerous bone marrow with healthy haematopoietic stem cells from an immunologically matched volunteer. The donated stem cells engraft in the recipient's bone marrow, building an entirely new blood and immune system while providing a graft-versus-leukaemia effect that targets residual malignant cells.
Yes, it is an established, potentially curative treatment for acute leukaemia, marrow failure, and other blood disorders. Success rates depend on disease stage, patient age, remission status prior to conditioning, and HLA compatibility. Evidence from international registries shows the highest cure rates occur when patients undergo transplantation during early, complete remission.
Approximate costs in Turkey typically range from €55,000 to €110,000, compared with €130,000 to €260,000 in the UK and €250,000 or more in the US. The total figure depends on international donor search fees, conditioning protocols, medication requirements, and length of inpatient isolation.
Unlike cosmetic surgery, before and after progress is measured internally through blood counts, marrow aspirates, and donor chimerism tests. Patients initially experience fatigue, hair loss, and weight changes during conditioning and isolation, followed by gradual physical recovery, hair regrowth, and energy restoration over six to twelve months as immune function rebuilds.
Initial engraftment occurs in two to four weeks, followed by one to two months of outpatient monitoring near the clinic. Returning to daily activities and work generally takes six to twelve months, while complete immune reconstitution and childhood re-vaccinations require twelve to twenty-four months under haematological supervision.
The stem cell infusion itself is not physically painful and is administered through a central venous catheter like a blood transfusion. However, conditioning chemotherapy causes significant side effects, including mouth sores (mucositis), nausea, fatigue, and temporary pain. Hospital teams provide tailored analgesic protocols, anti-emetics, and supportive care throughout every treatment stage.
When an allogeneic transplant is successful and full donor chimerism is established, the newly engrafted haematopoietic system is permanent. The donor cells continue producing red cells, white cells, and platelets for the rest of the recipient's life, maintaining ongoing immune surveillance against malignant cell recurrence.
The primary risks include graft-versus-host disease (GvHD), opportunistic infections due to profound immune suppression, conditioning toxicity affecting the liver or lungs, and graft rejection. Modern high-resolution HLA matching, HEPA-filtered isolation wards, and targeted prophylactic immunosuppressants help reduce these risks significantly in accredited transplant centres.
A matched sibling donor shares both biological parents and has an identical HLA match, which typically offers the lowest rate of graft-versus-host disease. A matched unrelated donor is an unrelated volunteer found through global registries; with modern 10/10 high-resolution HLA matching, long-term survival outcomes are comparable to sibling transplants.
Patients typically stay in Turkey for 90 to 120 days. This duration encompasses pre-transplant workup, one week of conditioning, three to four weeks of protective inpatient isolation until engraftment, and six to eight weeks of frequent outpatient monitoring to safely manage medication and early complications before flying home.
Patient stories